CCHT(SZ:000661) Zhi Tong Cai Jing·2025-11-14 12:16Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas listing applications, specifically addressing the case of Changchun High-tech (000661) and its fundraising and AI-related business details [1][2]. Group 1: Regulatory Requirements - CSRC has requested Changchun High-tech to clarify the use of raised funds and the specifics of its AI large model business [1][2] - The company must provide a legal opinion regarding the ownership structure of its controlling shareholder, Jilin Province Xinzhen Fund Partnership, and whether any legal restrictions on shareholding exist [1][2] - The company is required to explain the potential impact of its controlling shareholder's equity pledge on the control of the issuer and compliance with relevant regulations [1][2] Group 2: Business Operations - Changchun High-tech is described as an innovation-driven pharmaceutical group with a comprehensive product portfolio covering therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine [2] - The company is one of the few domestic pharmaceutical enterprises capable of achieving full industry chain capabilities in research and development, production, and commercialization across all major drug registration types in China [2] - The company has established a strong and diversified product portfolio in various therapeutic areas, including endocrine and metabolic diseases, women's health, immune and respiratory diseases, tumors, vaccines, and traditional Chinese medicine [2]